Literature DB >> 16079488

Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma.

Byoung-Seob Ko1, Soo Bong Choi, Seong Kyu Park, Jin Sun Jang, Yeong Eun Kim, Sunmin Park.   

Abstract

Our preliminary study demonstrated that 70% ethanol Cortidis Rhizoma extracts (CR) had a hypoglycemic action in diabetic animal models. We determined whether CR fractions acted as anti-diabetic agent, and a subsequent investigation of the action mechanism of the major compound, berberine ([C(20)H(18)NO(4)](+)), was carried out in vitro. The 20, 40 and 60% methanol fractions from the XAD-4 column contained the most insulin sensitizing activities in 3T3-L1 adipocytes. The common major peak in these fractions was berberine. Treatment with 50 microM berberine plus differentiation inducers significantly reduced triglyceride accumulation by decreased differentiation of 3T3-L1 fibroblasts to adipocytes and triglyceride synthesis. Significant insulin sensitizing activity was observed in 3T3-L1 adipocytes which were given 50 microM berberine plus 0.2 nM insulin to reach a glucose uptake level increased by 10 nM of insulin alone. This was associated with increased glucose transporter-4 translocation into the plasma membrane via enhancing insulin signaling pathways and the insulin receptor substrate-1-phosphoinositide 3 Kinase-Akt. Berberine also increased glucose-stimulated insulin secretion and proliferation in Min6 cells via an enhanced insulin/insulin-like growth factor-1 signaling cascade. Data suggested that berberine can act as an effective insulin sensitizing and insulinotropic agent. Therefore, berberine can be used as anti-diabetic agent for obese diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079488     DOI: 10.1248/bpb.28.1431

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  43 in total

Review 1.  Advance of studies on anti-atherosclerosis mechanism of berberine.

Authors:  Min Wu; Jie Wang; Long-tao Liu
Journal:  Chin J Integr Med       Date:  2010-05-16       Impact factor: 1.978

2.  Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats.

Authors:  Feng-Hao Geng; Guo-Hua Li; Xing Zhang; Peng Zhang; Ming-Qing Dong; Zhi-Jing Zhao; Yuan Zhang; Ling Dong; Feng Gao
Journal:  Br J Pharmacol       Date:  2016-04-05       Impact factor: 8.739

3.  Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats.

Authors:  Qin-He Yang; Si-Ping Hu; Yu-Pei Zhang; Wei-Ning Xie; Na Li; Gui-Yuan Ji; Na-Li Qiao; Xiu-Feng Lin; Tong-Yan Chen; Hai-Tao Liu
Journal:  Chin J Integr Med       Date:  2011-02-27       Impact factor: 1.978

4.  Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes.

Authors:  Tianjiong Lou; Zhongai Zhang; Zhilei Xi; Kang Liu; Lin Li; Baolin Liu; Fang Huang
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

5.  Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study.

Authors:  Li Liu; Yun-Li Yu; Jian-Song Yang; Yang Li; Yao-Wu Liu; Yan Liang; Xiao-Dong Liu; Lin Xie; Guang-Ji Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-13       Impact factor: 3.000

6.  Uncoupling protein-2 mediates the protective action of berberine against oxidative stress in rat insulinoma INS-1E cells and in diabetic mouse islets.

Authors:  Limei Liu; Jian Liu; Yuansheng Gao; Xiaoxing Yu; Gang Xu; Yu Huang
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

7.  Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism.

Authors:  Qian Zhang; Xinhua Xiao; Kai Feng; Tong Wang; Wenhui Li; Tao Yuan; Xiaofang Sun; Qi Sun; Hongding Xiang; Heng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-26       Impact factor: 2.629

Review 8.  Traditional chinese medicine in treatment of metabolic syndrome.

Authors:  Jun Yin; Hanjie Zhang; Jianping Ye
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-06       Impact factor: 2.895

9.  Efficacy of berberine in patients with type 2 diabetes mellitus.

Authors:  Jun Yin; Huili Xing; Jianping Ye
Journal:  Metabolism       Date:  2008-05       Impact factor: 8.694

10.  Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.

Authors:  Zhi-Quan Wang; Fu-Er Lu; San-Hua Leng; Xin-Sheng Fang; Guang Chen; Zeng-Si Wang; Li-Ping Dong; Zhong-Qing Yan
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.